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Extracts of B. subtilis contain somatostatin-like immunoactivity (I-20 pg 
~er g wet weight cells). Two major forms were detected, one with reactivity in 
~oth N-and C- terminal immunoassays similar to somatostatin-28 and a second 
Form reactive only in the C-terminal specific immunoassay similar to somato- 
~tatin-14. Both forms were active in a bioassay and the bioactivity was 
neutralized in the presence of antibody to the central, biologically active 
part of somatostatin-14. Preconditioned medium contained no detectable 
somatostatin whereas conditioned medium had 80-380 pg per liter. © 1985 kc~d~ie 
Press, Inc. 
Previous reports from our laboratory have described the presence of 
materials similar to vertebrate-type peptide hormones in unicellular eukaryotes 
and some bacterial strains (I-6). Most recently we reported the existence of 
materials in extracts of Escherichia coli resembling somatostatin (SRIF)(6). 
Two forms of SRIF-immunoactivity were found following HPLC purification: one 
form, somatostatin-28 (SRIF-28) was reactive in both N- and C-terminal 
specific immunoassays and somatostatin-14 (SRIF-14) that was only reactive in 
the C-terminal specific immunoasssay (6). 
To determine whether the presence of somatostatin-like immunoactivity 
(SRIF-LI) is widespread amongst bacteria we have searched for the presence of 
SRIF-LI in Bacillus subtilis grown in defined, synthetic medium. This report 
describes the presence of both SRIF~28 and SRIF-14 immunoactivity in B. 
subtilis and in addition demonstrates that the HPLC purified material was 
active in a bioassay for somatostatin. 
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MATERIALS AND METHODS 
Fermentation: Five batches of B. subtilis (no 61293, a gift of Dr. E. Freese, 
NIH, Bethesda) were grown in 50-100 iiter fermenters in synthetic, defined 
medium which contained;K2HPO 4 5mM, NH4(SO 4) 10mM, glutamic acid 20mM, glucose 
20mM, tryptophan 50~g/L, methionine 20ug/L, Mg++ 2mM, Ca++ 0.7mM, Mn÷+ 50~M, 
Zn÷+ I~M, Fe 5~M, Thiamine 2uM. At the end of the logarithmic growth phase 
cells were harvested by continuous centrifugation using a Sharpies centrifuge. 
Extraction: The cell paste obtained following centrifugtion was weighed and 
homogenized using a Manton Gaulin homogenizer. The homogenates were then 
extracted in 5-10 volumes (v/w) cold acid/ethanol (0.2N HC1/75% ethanol) as 
previously described 1,2,6). After overnight mixing at 4°C, this extract was 
centrifuged; the remaining supernatant concentrated by evaporation of the 
ethanol under nitrogen and then neutralized using 1.0N NaOH. The extact was 
boiled for 20 minutes, centrifuged, and trifluoroacetic acid (TFA) added to the 
remaining supernatant to a final concentration of 0.2%TFA. Unconditioned as 
well as conditioned medium from batches 2,3 and 5 were acidified using acetic 
acid and processed as for cells. 
Sep~Pak C18 Purification: Celis and medium were applied to SepPak C18 (reverse 
phase) disposable I ml cartridges; one cartridge per 10 g. wet weight of cells 
and one cartridge per 100 ml. of medium. Elution of the material that adsorbed 
to the Sep~Pak column was performed using acetonirile in 0.1% TFA. The 
material that eluted with 25-50% acetonitrile was kept for further purifi- 
cation. 
Biogel P-6 Chromatography: Further purification of the SRIF-LI eluting from 
the Sep-pak C18 columns was performed by Biogel P-6 column chromatography. 
Samples were applied and eluted in 0.01% formic acid; individual fractions were 
lyophilized extensively and tested for SRIF-LI (6). 
High Performance Liquid Chromatography (HPLC): Fractions from the Biogel 
columns that contained SRIF~LI were combined and further purified by reverse 
phase HPLC using C18 ~Bondapak (Waters Association) at a flow rate of 1.0 ml 
per minute using isocratfc elution with 28% acetonitrile in O.01%TFA (6). 
Radioimmunoassay: At each step of the purification process, SRIF-LI material 
was measured by a C-terminal specific immunoassay as previously described 
(4,6). Limits of detectability were reproducibly I-2 pg per assay tube with 
50% displacement of 10-15 pg per tube (6). Following HPLC purification SRIF-LI 
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as also measured by a N-terminal specific immunoassay as described (6). Lower 
imit of detectability in this assay was 40 pg per assay tube and 50% displace ~ 
Lent was 200 pg per tube. 
~omatostatin Bioassay: HPLC purified SRIF-LI was tested for biological 
Lctivity in an established bioassay for somatostatin (7). Briefly, the effect 
~f somatostatin on guinea pig oxyntic cell hydroxyl ion production is measured 
~y quantitative cytochemistry. Under the assay conditions somatostatin 
~timulates hydroxyl ion production. The hydroxyl ions are trapped by cobalt 
lydroxide which, in the presence of H2S forms a brown/black pigment of cobalt 
~ulfide. Cobalt sulfide is then quantified by scanning microdensitometry. The 
~ssay is sensitive to I0-14M somatostatin (7), and there is a linear 
lose~dependent increase in staining with concentrations of somatostatin from 
.05 through 50 pg/ml somatostatin -14. The biological activity of somatostatin 
-14 and -28 are indistinguishable and can be neutralized with an antiserum 
lirected towards the mid-portion of the somatostatin -14 molecule. 
RESULTS 
3iogel Purification: The SRIF~LI recovered from Sep-Pak C18 columns, when 
~hromatographed on Biogel P~6 columns eluted a broad peak (Figure I). 
~ecoveries from each column were between 75-85% of the SRIF-LI applied to the 
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Figure 1.Biogel P-6 Chromatography of Sep-Pak C18 purified extracts. Aliquots 
were applied to a 48 ml column (52cm x 0.gcm) and eluted with 0.01% formic 
acid. Individual 1.5 ml fractions were lyophilized, reconstituted in 
distilled water and tested for SRIF-LI using the C~terminal specific SRIF 
assay. SRIF-28 and SRIF-14 standards were run ~eparately (after the 
samples) under similar conditions. The arrows represent peak elution 
fractions for the synthetic standard preparations. 
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Table I 
Somatostatln-related Immunoactlvlty in Bacillus subtilis 
Immunoactive somatostatin 
C Terminal Assay 
Elutlon off Sep-Pak pg/G 
Batch Wet Blogel HPLC 




I 150 11.2 NT NT NT 376.9 
2 270 1.35 1.09 NT NT 89.8 
3 630 2.12 0.81 0.23 <41.4" 211.4 
4 900 0.72 1.86 0.81 NT NT 
5 600 37.3 21.6 20.3 < 4.2* 214.5 
NT=Not tested 
*Less than the assay detection limits. 
column, and blank runs had no detectable SRIF-LI. Between 0.8 and 22 pg 
SRIF-LI/g wet weight cells was recovered. Unconditioned medium had no 
detectable SRIF-LI, whereas conditioned medium had 80~380 pg/liter (Table I). 
HPLC Purification: SRIF-LI resolved into two major peaks on HPLC using an 
isocratic elution with 28% acetonitrile in 0.01% TFA (Figure 2). The 
early peak eluted with a retention time similar to SRIF-28 and was 
immunoactive in both the C-terminal as well as the N-terminal specfic 
immunoassays. The later peak eluted with a retention time similar to 
SRIF-14 and was only reactive in the C-terminal specific immunoassay 
(Figure 2). Recoveries of SRIF-LI from columns were 85-95% and blank runs 
before and after application of the samples contained no detectable 
SRIF-LI. 
Bioactivity: Synthetic SRIF~14 stimulated hydroxyl ion production by guinea pig 
gastric oxyntic cells in a dose dependent manner from .05 to 50 pg/ml. Serial 
dilutions of HPLC purified material from Bacillus also stimulated hydroxyl ion 
production (Figure 3). Both the early HPLC peak ("SRIF-28", figure 2) as well 
as the later peak ("SRIF-14") demonstrated reasonably parallel biological 
activity which was similar to that of the synthetic somatostatin-14 standard 
preparation. In addition the biological activity of each sample was inhibited 
almost completely by the presence of (C-terminal specific) anti~somatostatin 
antiserum (Figure 3). 
DISCUSSION 
Originally isolated from extracts of mammalian hypothalamus, SRIF is 
found widespread throughout vertebrate tissues and more recently in 
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Figure 2.Followlng Sep-Pak and Biogel chromatography batches 3-5 were further 
purified on HPLC. Batch 5 alone is represented. The allquots were 
applied to a ~Bondapak reverse phase column. Solvent A contained 0.01% 
TFA and solvent B contained 98% acetonltrile in 0.01% TFA. Flow rate was 
1.0 ml per minute. Initial elution was carried out for 40 min under 
isocratic conditions using 28% acetonltrile and then the gradient was 
increased to 80% acetonitrile. Fractions were collected, lyophilized, 
reconstituted in water and assayed for SRIF-LI using the C-terminal (upper 
panel) as well as the N~terminal assay (lower panel). SRIF-28 and SRIF-14 
standards were run separately and blank runs were devoid of SRIF-LI. 
invertebrates (8,9,10). We have reported its presence in the unicellular 
protozoan Tetrahymena pyriformis and more recently in Escherichia coli 
(4,6). The presence in Bacillis subtilis of material closely resembling 
somatostatin adds support to the concept that somatostatin-like substances 
may be widespread among unicellular eukaryotes and prokaryotes. 
The SRIF-LI immunoactivity recovered from the B. subtilis resolved into 
two peaks on HPLC, resembling SRIF-28 and SRIF-14. Both peaks were bioactive 
in a typical somatostatin bioassay which is characteristic of vertebrate 
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Figure 3.Hydroxyl ion production by guinea pig oxyntic cells was measured as the 
intensity of staining with cobalt sulfide detected by mlcrodensitometry and is 
presented as the mean integrated extinction times 100 as an index of this 
activity. Synthetic somatostatln -14 (0-0) was used as the standard and ([3{3) 
represents the early HPLC peak ("SRIF-28-11ke") whereas (~-~) represents the 
late HPLC peak ("SRIF-14-11ke.) from figure 2. 
SRIF-28 and SRIF-14 (11,12). It is interesting to speculate that a 
precursor-product relationship similar to that in vertebrate species may be 
present in B. subtilis. However such a relationship has not been demonstrated 
by the present studies. 
Quantities of SRIF-LI in Bacillus cells ranged widely probably 
reflecting marked variations in recoveries of endogenous SRIF-LI during 
multiple purification procedures. Alternatively SRIF-LI production may 
vary with growth conditions, which were not optimized in our cultures. 
Contamination of the extracts by exogenously added SRIF-LI was excluded by 
the absence of SRIF-LI in unconditioned medium processed in an identical 
manner. In addition blank runs were devoid of SRIF-LI and recoveries from 
chromatography columns were always slightly less than 100%. 
It is apparent that the SRIF-LI identified by molecular sieve 
chromatography contained material with MW similar to somatostatin -28 and 
somatostatin -14. However, there was also significant immunoactive 
somatostatin eluting in other regions which may represent other molecular 
species of somatostation (13). 
Final confirmation of these findings will require isolation and 
sequencing of the gene(s) coding for SRIF in the prokaryotes. 
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